glp-1 shortage canada news today GLP-1 prescription trends through March 2026 3 million Canadians take GLP-1

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda, Victoza) have rapidly become some of the most widely prescribed medications for weight loss and metabolic health

[PMID: 37940910]

And the data from the SURMOUNT-OSA trial is remarkable

Oral semaglutide formulations face bioavailability challenges - the medication must survive the digestive system to be absorbed

Design In the obesity trial, 338 participants (mean age 48 years, 48% women, mean BMI 37.3 kg/m 2 ) were randomised (2:1:1:1:1:2:2) to retatrutide 1 mg, 4 mg (titration), 4 mg (no titration), 8 mg (slow titration), 8 mg (fast titration), 12 mg or placebo over 48 weeks [45]

It is a master producer of butyratea short-chain fatty acid that triggers your body to release its own fullness hormones, GLP-1 and PYY